What is claimed is:

1. ~~A~~ Use of synthetic ~~pediatric formula~~ composition comprising ~~a~~ 0.001 mg/mL to 20mg/mL of the human milk oligosaccharide 2' - fucosyllactose; 0.001 µg/mL to 10 µg/mL of a carotenoid; and 0.025 mg/mL to 0.130 mg/mL of a long chain polyunsaturated fatty acid for the manufacture of a medicament for the treatment and/or prevention of an inflammatory condition or disease in an infant, toddler, or child by reducing said inflammation..

2. The ~~synthetic pediatric formula~~ use of claim 1, wherein the ~~human milk oligosaccharide is selected from the group consisting of 6'-sialyllactose, 2'-fucosyllactose, and combinations thereof and~~ the long chain polyunsaturated fatty acid is selected from the group consisting of linoleic acid, linolenic acid, arachidonic acid, docosahexaenoic acid, eicosapentaenoic acid, docosapentaenoic acid, and combinations thereof.

3. The ~~synthetic pediatric formula~~ use of claim 2, wherein the long chain polyunsaturated fatty acid is docosahexaenoic acid.

~~4. The synthetic pediatric formula of claim 2, wherein the human milk oligosaccharide is 6'-sialyllactose.~~

~~5. The synthetic pediatric formula of claim 4, wherein the 6'-sialyllactose is present in a concentration of 0.001 mg/mL to 20 mg/mL.~~

~~6. The synthetic pediatric formula of claim 5, wherein the 6'-sialyllactose is present in a concentration of 0.001 mg/mL to less than 0.25 mg/mL.~~

~~7. The synthetic pediatric formula of claim 5, wherein the 6'-sialyllactose is present in a concentration of from greater than 0.4 mg/mL to 20 mg/mL.~~

~~8. A synthetic pediatric formula comprising a human milk oligosaccharide and 0.001 µg/mL to 10 µg/mL of a carotenoid.~~

~~4~~9. The ~~synthetic pediatric formula~~ use of claim ~~8~~1, wherein the carotenoid is present in a concentration of 0.001 µg/mL to 5 µg/mL.

~~10. The synthetic pediatric formula of claim 8, wherein the human milk oligosaccharide is selected from the group consisting of 6'-sialyllactose, 2'-fucosyllactose, and combinations~~

~~thereof and the carotenoid is selected from the group consisting of lutein, lycopene, beta-carotene, and combinations thereof.~~

~~11. A composition comprising (a) a human milk oligosaccharide and (b) at least one of (i) 0.025 mg/mL to 0.130 mg/mL of a long chain polyunsaturated fatty acid, and (ii) 0.001 μg/mL to 10 μg/mL of a carotenoid, for use in the treatment and/or prevention of an inflammatory condition or disease in an infant, toddler, or child by reducing said inflammation.~~

~~12. The composition of claim 11, wherein the human milk oligosaccharide is selected from the group consisting of 6'-sialyllactose, 2'-fucosyllactose, and combinations thereof and the long chain polyunsaturated fatty acid is selected from the group consisting of linoleic acid, linolenic acid, arachidonic acid, docosahexaenoic acid, eicosapentaenoic acid, docosapentaenoic acid, and combinations thereof.~~

~~13. The composition of claim 11, wherein the long chain polyunsaturated fatty acid is docosahexaenoic acid.~~

~~14. The composition of claim 11, wherein the human milk oligosaccharide is 6'-sialyllactose.~~

~~15. The composition of claim 14, wherein the 6'-sialyllactose is present in a concentration of 0.001 mg/mL to 20 mg/mL.~~

5~~16~~. The ~~composition~~ use of claim 1~~1~~, wherein the inflammatory disease or condition is virus-induced.

6. The use of claim 1, wherein the carotenoid is lycopene.

7. The use of claim 1, wherein the treatment and/or prevention of an inflammatory condition or disease comprises regulation of an inflammatory response to an infection or other injury.

8. The use of claim 1, wherein the composition further comprises a second human milk oligosaccharide.

9. The use of claim 8, wherein the second human milk oligosaccharide is selected from the group consisting of 3'-sialyllactose, 6'-sialyllactose, and lacto-N-neotetraose.

10. The use of claim 5, wherein the inflammatory disease or condition is induced by a respiratory virus.

11. The use of claim 10, wherein the respiratory virus is respiratory syncytial virus.

12. The use of claim 9, wherein the composition comprises at least about 0.1 mg/mL of the 2'-fucosyllactose and 0.001 μg/mL to 5 μg/mL of the carotenoid.